TY - JOUR
T1 - Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study
AU - Griffith, Kathleen A.
AU - Dorsey, Susan G.
AU - Renn, Cynthia L.
AU - Zhu, Shijun
AU - Johantgen, Mary E.
AU - Cornblath, David R.
AU - Argyriou, Andreas A.
AU - Cavaletti, Guido
AU - Merkies, Ingemar S. J.
AU - Alberti, Paola
AU - Postma, Tjeerd J.
AU - Rossi, Emanuela
AU - Frigeni, Barbara
AU - Bruna, Jordi
AU - Velasco, Roser
AU - Kalofonos, Haralabos P.
AU - Psimaras, Dimitri
AU - Ricard, Damien
AU - Pace, Andrea
AU - Galie, Edvina
AU - Briani, Chiara
AU - Dalla Torre, Chiara
AU - Faber, Catharina G.
AU - Lalisang, Roy I.
AU - Boogerd, Willem
AU - Brandsma, Dieta
AU - Koeppen, Susanne
AU - Hense, Joerg
AU - Storey, Dawn J.
AU - Kerrigan, Simon
AU - Schenone, Angelo
AU - Fabbri, Sabrina
AU - Valsecchi, Maria Grazia
PY - 2014/6
Y1 - 2014/6
N2 - Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.
AB - Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.
KW - assessment
KW - chemotherapy
KW - neurophysiology
KW - peripheral neuropathy
U2 - 10.1111/jns5.12064
DO - 10.1111/jns5.12064
M3 - Article
C2 - 24814100
SN - 1085-9489
VL - 19
SP - 127
EP - 135
JO - Journal of the Peripheral Nervous System
JF - Journal of the Peripheral Nervous System
IS - 2
ER -